Magic mushroom therapy targets Cancer-Related anxiety in new trial
NCT ID NCT07072728
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a single dose of NPX-5 (a psilocybin drug) combined with talk therapy can reduce severe anxiety in people who have trouble adjusting to a cancer diagnosis. About 87 adults aged 18–80 with moderate-to-severe anxiety will receive one of three doses (25 mg, 10 mg, or 1 mg) during an 8-hour therapy session. The goal is to see if the treatment safely lowers anxiety and improves quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUSTMENT DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Empax Centre
RECRUITINGLeederville, Western Australia, 6007, Australia
-
Mind Medicine Australia Clinic
RECRUITINGAbbotsford, Victoria, 3067, Australia
-
Paratus Clinical Research Melbourne
RECRUITINGNorthcote, Victoria, 3070, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?